Page last updated: 2024-10-31

midodrine and 2019 Novel Coronavirus Disease

midodrine has been researched along with 2019 Novel Coronavirus Disease in 2 studies

Midodrine: An ethanolamine derivative that is an adrenergic alpha-1 agonist. It is used as a vasoconstrictor agent in the treatment of HYPOTENSION.
midodrine : An aromatic ether that is 1,4-dimethoxybenzene which is substituted at position 2 by a 2-(glycylamino)-1-hydroxyethyl group. A direct-acting sympathomimetic with selective alpha-adrenergic agonist activity, it is used (generally as its hydrochloride salt) as a peripheral vasoconstrictor in the treatment of certain hypotensive states. The main active moiety is its major metabolite, deglymidodrine.

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's2 (100.00)2.80

Authors

AuthorsStudies
Narasimhan, B1
Aggarwal, D1
Satish, P1
Kantharia, B1
Aronow, WS1
Abbate, G1
De Iulio, B1
Thomas, G1
Priday, A1
Biondi-Zoccai, G1
Markley, R1
Abbate, A1

Reviews

2 reviews available for midodrine and 2019 Novel Coronavirus Disease

ArticleYear
Postural orthostatic tachycardia syndrome: pathophysiology, management, and experimental therapies.
    Expert opinion on investigational drugs, 2022, Volume: 31, Issue:10

    Topics: COVID-19; Deamino Arginine Vasopressin; Erythropoietin; Fludrocortisone; Humans; Immunoglobulins, In

2022
Postural Orthostatic Tachycardia Syndrome After COVID-19: A Systematic Review of Therapeutic Interventions.
    Journal of cardiovascular pharmacology, 2023, Jul-01, Volume: 82, Issue:1

    Topics: Adrenergic beta-Antagonists; Adult; COVID-19; Female; Heart Rate; Humans; Male; Middle Aged; Midodri

2023